Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at for patienter med Fabry sygdom kan Fabrazyme give kliniske fordele på lang sigt.
The Committee for Medicinal Products for Human Use (CHMP) decided that, for patients with Fabry disease, treatment with Fabrazyme might provide long-term clinical benefits.